Loading clinical trials...
Loading clinical trials...
A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Conditions
Interventions
AXR-270 Low Dose
AXR-270 High Dose
+1 more
Locations
1
United States
AxeroVision, Inc.
Carlsbad, California, United States
Start Date
June 16, 2020
Primary Completion Date
December 1, 2020
Completion Date
December 31, 2020
Last Updated
July 21, 2023
NCT06220474
NCT07453212
NCT06542276
NCT06064071
NCT03652337
NCT05577910
Lead Sponsor
AxeroVision, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions